



King's Research Portal

DOI:

[10.1111/bph.12363](https://doi.org/10.1111/bph.12363)

Document Version

Peer reviewed version

[Link to publication record in King's Research Portal](#)

Citation for published version (APA):

Nederlof, R., Eerbeek, O., Hollmann, M., Southworth, R., & Zuurbier, C. J. (2014). Targeting Hexokinase II to mitochondria to modulate energy metabolism and reduce ischemia-reperfusion injury in heart. *British Journal of Pharmacology*, 171(8), 2067-2079. <https://doi.org/10.1111/bph.12363>

Citing this paper

Please note that where the full-text provided on King's Research Portal is the Author Accepted Manuscript or Post-Print version this may differ from the final Published version. If citing, it is advised that you check and use the publisher's definitive version for pagination, volume/issue, and date of publication details. And where the final published version is provided on the Research Portal, if citing you are again advised to check the publisher's website for any subsequent corrections.

General rights

Copyright and moral rights for the publications made accessible in the Research Portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognize and abide by the legal requirements associated with these rights.

- Users may download and print one copy of any publication from the Research Portal for the purpose of private study or research.
- You may not further distribute the material or use it for any profit-making activity or commercial gain
- You may freely distribute the URL identifying the publication in the Research Portal

Take down policy

If you believe that this document breaches copyright please contact librarypure@kcl.ac.uk providing details, and we will remove access to the work immediately and investigate your claim.

Targeting Hexokinase II to mitochondria to modulate energy metabolism and reduce ischemia-reperfusion injury in heart

Rianne Nederlof,¹ Otto Eerbeek,² Markus W Hollmann¹, Richard Southworth³, Coert J Zurbier¹

¹Laboratory of Experimental Anesthesiology and Intensive Care, Department of Anesthesiology, and ²Department of Anatomy, Embryology and Physiology, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands; Department of Imaging Chemistry and Biology, Division of Imaging Sciences and Biomedical Engineering, King's College, London, United Kingdom.

Abbreviated title: mtHK as protector against IR injury

Address of correspondence:

Dr. C. J. Zurbier

Department of Anaesthesiology,

Academic Medical Centre, University of Amsterdam

Meibergdreef 9, 1105 AZ Amsterdam, The Netherlands

Phone: + 31 (20) 566 5259; Fax: + 31 (20) 6979441

E-mail: c.j.zurbier@amc.uva.nl

This article has been accepted for publication and undergone full peer review but has not been through the copyediting, typesetting, pagination and proofreading process, which may lead to differences between this version and the Version of Record. Please cite this article as doi: 10.1111/bph.12363

Summary:

Mitochondrially-bound hexokinase II (mtHKII) has long been known to confer cancer cells with their resilience against cell death. More recently, mtHKII has emerged as a powerful protector against cardiac cell death. mtHKII protects against IR injury in skeletal muscle and heart, attenuates cardiac hypertrophy and remodelling, and is one of the major end-effectors through which ischemic preconditioning protects against myocardial ischemia-reperfusion injury. Mechanisms of mtHKII cardioprotection against reperfusion injury entail the maintenance of regulated OMM permeability during ischemia and reperfusion resulting in stabilisation of mitochondrial membrane potential, the prevention of OMM breakage and cytochrome C release, and reduced ROS production. Increasing mtHK may also have important metabolic consequences, such as improvement of glucose-induced insulin release, prevention of acidosis through enhanced coupling of glycolysis and glucose oxidation, and inhibition of fatty acid oxidation. Deficiencies in expression and distorted cellular signalling of HKII may contribute to the altered sensitivity of diabetes to cardiac ischemic diseases. The interaction of HKII with the mitochondrion constitutes a powerful endogenous molecular mechanism to protect against cell death in almost all cell types examined (neurons, tumours, kidney, lung, skeletal muscle, heart). The challenge is now to harness mtHKII in the treatment of infarction, stroke, elective surgery and transplantation. Remote ischemic preconditioning, metformin administration and miR-155/miR-144 manipulations are potential means of doing just that.

Key words: ischemia-reperfusion injury; mPTP; cell death; diabetes; glycolysis, mitochondria

Abbreviations: AMPKamp-activated protein kinase; ANTadenine nucleotide transporter; CABGcoronary artery bypass grafting; CypDcyclophilin D; CytCcytochrome C; ERendoplasmic reticulum; G6Pglucose-6-phosphate; HKhexokinase; HSP90heat shock protein 90; IMM inner mitochondrial membrane; IRischemia-reperfusion; IPCischemic preconditioning; MImyocardial infarction; miRmicro RNA; mPTPmitochondrial permeability transition pore; mtHKmitochondrially-bound hexokinase; OMMouter mitochondrial membrane; PGC-1 β PPAR gamma coactivator 1 beta; RIPCreremote ischemic preconditioning; ROSreactiveoxygenspecies; VDACvoltage-dependent anion channel

INTRODUCTION

The two leading causes of human mortality are cancer and cardiovascular disease. Curiously, the directed goal of therapy against these diseases is diametrically opposed: in cancer we strive to kill the tumour cells, whereas in heart disease we strive to protect cardiac cells from being killed. The question arose whether the processes that promote cell survival in cancer cells could potentially be used in promoting survival in the heart, and whether our understanding of the death processes in the heart could be harnessed in the treatment of cancer. The cancer literature has suggested that the resilience of cancer cells against cell death is, at least partly, due to highly elevated levels of HKII bound to mitochondria (Pedersen, 2007). Knowing that mitochondrial dysfunction has emerged as a major mediator of cell death in ischemia-reperfusion injury of the heart, we considered the possibility that HKII is one of the critical regulators of mitochondrial dysfunction in cardiac IR injury. This consideration was primarily based on the pioneering work by others demonstrating the pivotal role of HK in mitochondrial function and cell death in non-cardiovascular research fields. Instrumental in these HK pioneering studies were the discoveries of HK binding to and regulation of mitochondrial VDAC (Fiek *et al.*, 1982; Brdiczka, 1990; Forte *et al.*, 1987; Rostovtseva *et al.*, 2005; Rostovtseva *et al.*, 2008A), and the regulatory role of HK in mitochondrial pore formation (Nakshima *et al.*, 1986; Marzo *et al.*, 1998). Various work by us and others have now clearly demonstrated that mitochondrially-bound HKII is indeed a major determinant of infarct size and may constitute one of the end-effectors of ischemic preconditioning. Mitochondrial hexokinase II (and I) affects mitochondrial membrane potential and ROS production, regulates mPTP, and may also determine the direction of cardiac metabolic flux. This review summarizes current knowledge about the role of mitochondrially-bound hexokinase in cardioprotection and cardiac ischemia-reperfusion injury, adding mtHKII as a new target that may prove useful in the quest to reduce mortality due to cardiovascular disease.

The Hexokinase Family

The first step in the metabolism of glucose is its phosphorylation upon entrance into the cell. Sufficient and rapid phosphorylation is important to maintain the steep gradient of glucose concentration over the plasma membrane to drive continuous glucose uptake through the GLUT transporters, as well as to render glucose polar, and therefore incapable of exiting the cell. Glucose phosphorylation is catalyzed by the enzyme hexokinase, of which four isozymes are present within mammalian tissue. HKI, II and III are isozymes of 100 kDa, displaying high affinity for glucose ($K_m \leq 0.3$ mM) and product inhibition for G6P ($K_i \leq 0.1$ mM), whereas HKIV (glucokinase) is 50 kDa in size, has low affinity for glucose (half-saturation at about 8 mM glucose) and does not show product inhibition at physiological levels of G6P (Wilson, 2003). Importantly, HKI and II contain a hydrophobic amino terminal mitochondrial binding motif, which is not present in the HKIII and IV isoforms.

HKI is ubiquitously expressed in almost all mammalian tissues, is largely unresponsive to hormonal and prevailing metabolic conditions, and can be considered more of a house keeping protein. Surprisingly, despite being a glycolytic enzyme, and with glycolysis mainly being thought of as a cytosolic process, HKI is predominantly associated with mitochondria (Crane *et al.*, 1953; Johnson, 1960, Abraham *et al.*, 1964). It is suggested (Wilson, 1995, John *et al.*, 2011) that HKI principally performs a catabolic function, channelling glucose into glycolysis for ATP production. In contrast, HKII is more variably located in either the cytosol or at the mitochondrial outer membrane, and is mostly expressed in insulin-sensitive tissue

such as heart, skeletal muscle and adipose tissue. When situated in the cytosol it directs glucose into glycogen synthesis, while when bound to mitochondria it primarily directs glucose into glycolysis (John *et al.*, 2011). HKII expression levels and localization are highly regulated by (patho) physiology, hormones and metabolic state (Wilson, 2003; Heikkinen *et al.*, 2000). In contrast to the abundance of HKI and HKII, HKIII shows low expression in most mammalian tissues, being most highly represented in lung, liver and spleen (Heumann *et al.*, 1974; Furuta *et al.*, 1996). Finally, HKIV is traditionally regarded as a glucose-sensing enzyme (although other HK isoforms also display glucose-sensing properties), associated with regulating insulin-release by pancreatic β -cell. This glucokinase is mainly expressed in liver and the pancreas, but can also be found in certain parts of the brain and gut (Postic *et al.*, 2001).

Mitochondrial Hexokinase in Cancer

As early as 1924, the pioneering work of the Nobel prize winner Otto Warburg (Warburg, 1924) associated malignant, aggressive tumour growth with increased rates of aerobic glycolysis and increased lactate production, a signature now known as the Warburg effect (Pedersen, 2007). It took another fifty years to demonstrate mitochondrial HKII as a key molecular governor of this increased glycolysis (Bustamante *et al.*, 1977; Bustamante *et al.*, 1981), with the expression of HKII (sometimes HKI) being increased often more than 100-fold. Activation of the PI3K/Akt pathway, one of the most frequently mutated pathways in cancer (Shaw *et al.*, 2006), and activation of PKA and PKC pathways, also commonly seen in cancers, may explain this increased HKII expression. DNA demethylation and HKII gene amplification has also been suggested to play a role (Mathulpa *et al.*, 2009), as has the increased expression of hypoxia-inducible factor HIF1 α (Keith *et al.*, 2012; Semenza *et al.*, 2003). Although Warburg originally hypothesized that the increased reliance of tumours on glycolysis was due to impairments in mitochondrial function, it is now known that this is not the case. Mitochondria from tumours can still have normal oxidative phosphorylation with intact ATP synthetic capacity; however, they are often reprogrammed towards biosynthetic pathways supporting tumour proliferation, such that glucose and glutamine become important substrates feeding rewired anabolic pathways (Ward *et al.*, 2012). Thus, the increased HKII expression and its binding to mitochondria not only facilitates increased aerobic glycolysis and lactate production (John *et al.*, 2011), but also the channelling of glycolytic substrates into biosynthetic pathways for which mitochondria play a crucial role. The increase in the proportion of HKII that is bound to mitochondria also provides the cancer cell with resilience to cell death. The exact mechanism of this protection has not yet been elucidated, but it is known that glucose is necessary in order for mtHKII to inhibit apoptosis, indicating that this is an active process requiring glucose phosphorylation (Gottlob *et al.*, 2001). Targeting the binding between HKII and mitochondria is currently actively pursued as a possible treatment against aggressive proliferative tumours. Such targeting may be achieved with 3-bromopyruvate (Mathupala *et al.*, 2009), methyl jasmonate (Goldin *et al.*, 2008), dichloroacetate (Michelakis *et al.*, 2010), the antifungal compounds clotrimazole and bifanazole (Penzo *et al.*, 1998), and some traditional Chinese medicinal plants (Wei *et al.*, 2013). However, such treatment comes with a price. Our recent data (Smeele *et al.*, 2011A) showing the high sensitivity of heart towards disruption of mtHKII binding and the immediate development of cardiac cell death, is a direct warning against any such treatment being a global, whole-body treatment. A nice example of this phenomenon is the use of anthracyclines in cancer chemotherapy, which, while very effective in cancer treatment have to be very carefully titrated because of their severe cardiotoxicity. It has been suggested that

this cardiotoxicity may be mediated in part by mito-HK dissociation via inhibition of Akt signalling (Pastorino *et al.*, 2005). Thus it is of paramount importance that these drugs target the cancer cell through localized delivery to the tumour (Ko *et al.*, 2012) or using compounds that are only taken up by the cancer cell through selective cancer-expressed transporters (Birsoy *et al.*, 2013).

Mitochondrial hexokinase and protection in non-cardiac tissues

Although the primary focus of this review is on the heart, mitochondrial hexokinase has been shown to protect against stressors in several other organs and tissues. We demonstrated that decreased (mitochondrial) HKII increased IR injury in skeletal muscle (Smeele *et al.*, 2010; Smeele *et al.*, 2012). In fact, skeletal muscle IR injury was very sensitive to reductions in HKII (50% HKII reduction increased IR-induced cell necrosis from 36% to 76%; Smeele *et al.*, 2012), probably because HKII is the major HK isoform in skeletal muscle. Bryson *et al.* (2002) and Gall *et al.* (2011) showed that increased HK activity protects kidney epithelial cells against oxidant injury, whereas Ahmad *et al.* (2002) demonstrated that HKII protected human lung epithelial cells against hyperoxia and oxidative stress. Finally, mtHKII protects against neurodegeneration in models of Parkinson's disease (Gimenez-Cassina *et al.*, 2009; Corona *et al.*, 2010). Therefore, it seems that the interaction of HK with mitochondria constitute an endogenous cellular protective mechanism against cell death that is operative in many tissues and organs.

Mitochondrial Hexokinase and Metabolism

Early observations (Bessman *et al.*, 1980; Wilson, 1995), later supported by various other researchers, demonstrated that mitochondrially bound hexokinase preferentially uses mitochondrially produced ATP (in contrast to cytosolic ATP), with direct channelling of the produced ADP back into the mitochondria. Thus one major metabolic consequence of HK translocation to the mitochondria is that the ATP sensitivity of glucose phosphorylation is shifted from a cytosolic to a mitochondrial ATP source. Surprisingly, however, it remains unknown what the metabolic consequences of this translocation *per se* are in terms of oxygen consumption and energy substrate selection in intact organs/tissues. The role of mtHK in cell death, however, is better understood. Several seminal studies have now clearly shown the association between mtHK disruption and cell death, induced by stimuli such as H₂O₂ and/or UV irradiation in cellular studies (Gottlob *et al.*, 2001; Pastorino *et al.*, 2002; Bryson *et al.*, 2002; Ahmad *et al.*, 2002) or ischemia-reperfusion in intact organs and tissues (Smeele *et al.*, 2011A, 2012; Pasdois *et al.*, 2013). There are indications that enhancing mtHKII may increase (glucose-mediated) oxidative phosphorylation and therefore overall energy production in permeabilised human fibres from dilated atria (Roosima *et al.*, 2013). These findings are in line with older literature showing that hexokinase can display high control strength over respiration in isolated mitochondria (Groen *et al.*, 1982). Interestingly, it has also been suggested that an increased translocation of HKI to mitochondria increases the glucose sensitivity of the pancreatic β -cell to release insulin (Rabuazzo *et al.*, 1997). Whether mtHK may affect cardiac (and skeletal muscle) insulin sensitivity is unknown. Clearly, more work needs to be done to answer these important questions as to how mtHKII affects metabolism of the intact heart.

Older literature indicates that mtHK not only affects glucose metabolism, but may also regulate cardiac fatty acid oxidation. Mitochondrial hexokinase inhibits palmitoyl-CoA

synthetase through competition for ATP and thereby inhibiting palmitate activation at the OMM in isolated mitochondria (de Jong *et al.*, 1970). The reported decrease in mtHK associated with diabetes (Katzen *et al.*, 1970) may therefore be a contributing factor to the often increased fatty acid metabolism in diabetic hearts. The reciprocal relationship was demonstrated by Southworth *et al.* who showed that perfusion of isolated hearts with fatty acids dislodged HKI and HKII from mitochondria (Southworth *et al.*, 2007). Thus, mtHK seems to be an ideal localization hub for the well-known competition between glucose and fatty acid metabolism and the regulation thereof.

Mitochondrial hexokinase in Cardiovascular Diseases (Figure 1)

HKI and HKII are both present in the heart. In adult mouse heart, HKI and HKII contribute approximately equally to total cardiac hexokinase activity (Smeele *et al.*, 2011B), depending on the age and the nutritional/pathophysiological condition of the animal. Few data are available for human heart, except for a recent report by Roosimaa *et al.* (2013) which indicates that in non-dilated human atrial tissue, HKI is the most abundant isoform. In mouse and human skeletal muscle (Smeele *et al.*, 2011B; Mandarino *et al.*, 1995) however, HKII accounts for >80% of total HK activity.

IPC Protection against I/R injury through increased mtHKII: The discovery that short, non-lethal periods of ischemia activate an endogenous cardiac protection program against long, lethal, periods of ischemia led to a highly intensified research effort to elucidate the cellular mechanisms. This phenomenon was called ischemic preconditioning (IPC; Murry *et al.* 1986). Subsequent research demonstrated that IPC cellular signalling converged on the mitochondrion, and was associated with alterations in glycolysis (Murphy *et al.*, 2008; Murry *et al.*, 1986). Work from our laboratory at that time also noticed this interaction between glycolysis and mitochondrial function following non-lethal periods of ischemia. We demonstrated that the activation of mitochondrial oxygen consumption, due to an instantaneously increased cardiac workload (Zuurbier *et al.*, 1997; Van Beek *et al.*, 1998), was slowed following non-lethal periods of ischemia. However, no such slowing was observed when glycolysis was bypassed using high concentrations of pyruvate or lactate (Zuurbier *et al.*, 2002). In other words, the changes observed in mitochondrial function following non-lethal ischemia were precipitated through changes evoked in glycolysis. After having established that the alterations in glycolysis were not due to alterations in the pentose phosphate pathway (Zuurbier *et al.*, 2004), translocation of HK with non-lethal periods of ischemia became a likely candidate (Zuurbier *et al.*, 2009). Finally, we demonstrated that reversible ischemia such as IPC induced a translocation of the glycolytic enzyme HK to the mitochondria (Zuurbier *et al.*, 2005; Gürel *et al.*, 2009). This led us to the hypothesis that IPC could, at least partly, be attributed to increased HKII trafficking to the mitochondria (Zuurbier *et al.*, 2009). This hypothesis was confirmed by subsequent studies showing loss of IPC protective effects with a peptide blocking mito-HKII binding (Smeele *et al.*, 2011A), and increased IR injury with partial deletion of the HKII gene in both heart and skeletal muscle (Smeele *et al.*, 2010, 2012; Wu *et al.*, 2011). This work was recently confirmed by findings in Halestrap's laboratory, showing a close correlation between cardiac infarct size and the extent of mitochondrial HKII dissociation (Pasdois *et al.*, 2013).

IR, post-MI, regeneration: HK expression and cellular localisation changes dramatically during and after periods of ischemia. During prolonged cardiac ischemia there is an increase in cytosolic HK activity (Correa *et al.*, 2008), that can be explained by solubilisation of HKII (but not HKI) from the mitochondria (Gürel *et al.*, 2009; Pasdois *et al.*, 2011). The

mechanism of HK detachment from the mitochondria during ischemia is, at least partly, related to acidification and increases in G6P (Pasdois *et al.*, 2013). The endogenous adaptation following ischemia in cardiac tissue is associated with increases (~ 30-70%) in total and mitochondrial HK (McFalls *et al.*, 2002; Wu *et al.*, 2011; Yeih *et al.*, 2011; Miyamoto *et al.*, 2010). Large increases (200-300%) in HK activity were also observed in regenerated skeletal muscle 2 weeks after the IR insult (Smeele *et al.*, 2012). It thus seems that following an ischemic episode there is increased HK expression, presumably enhancing biosynthetic pathways for regeneration and growth and to offer protection against recurrent episodes of ischemia.

Hypertrophy and Heart failure: During pressure overload-induced cardiac hypertrophy, mtHKII and total HKII protein content have been shown to increase (Wu *et al.*, 2012; Riehle *et al.*, 2011). Increased HKII expression was also recently reported in dilated human atria (Roosima *et al.*, 2013). Genetic reductions in HKII resulted in exaggerated cardiac hypertrophy in a pressure-overload model (Wu *et al.*, 2012). These data suggest that the increased HKII expression in pressure-overloaded hearts is an adaptive response, possibly attenuating hypertrophy through diminishing oxidative stress (Wu *et al.*, 2012). Therapeutic enhancement of tissue HKII during this hypertrophic stage may therefore be a potentially beneficial approach. Interestingly, while mild pressure-overload results in a relatively compensated hypertrophy associated with increases in HKII, the same procedure in animals deficient for PGC-1 β resulted in decreased HKII levels, decompensated hypertrophy, and evidence of increased oxidative stress (Riehle *et al.*, 2011). This data suggest that PGC-1 β , a regulator of mitochondrial biogenesis and genes encoding for mitochondrial metabolism, is needed to maintain cardiac function following pressure overload by possibly preserving HKII expression and preventing oxidative stress. Cardiac HKII has also been shown to be severely reduced in a pacing-induced heart failure model in pigs (Lionetti *et al.*, 2009). While these data suggest that the development of heart failure is associated with decreases in HKII, further studies are warranted to examine whether the reduced HKII protein levels are cause or consequence of cardiac failure.

Hyperglycemia and Diabetes: Hyperglycemia in the clinical condition is currently viewed as an important risk factor for poor clinical outcome. In addition, the presence of hyperglycemia in the pre-diabetic state is a strong predictor of developing diabetic disease. Acute hyperglycemia has been shown to induce the detachment of HK from mitochondria (Da-Silva *et al.*, 2004; Pasdois *et al.*, 2013), which may underlie its pathology. During the development of diabetes, there is a shift in cardiac metabolism away from glucose metabolism towards fatty acid metabolism. This shift is generally associated with significant decreases in cardiac and muscle HKII protein content without alterations in HKI protein content (Katzen *et al.*, 1970; Vestergaard *et al.*, 1995). The diabetic heart displays an altered response to IR and IPC, with short-term diabetes frequently offering protection against IR and attenuated IPC potential, and long-term diabetes resulting in worsened outcome after IR and loss of IPC protective effects (Miki *et al.*, 2012). It is possible that changes in cardiac HK contribute to such an altered response of diabetic heart to IR and IPC. Indeed, we have demonstrated that the increased protection against IR and the attenuation of IPC in the short-term type I diabetic heart are associated with altered mitochondrial HK binding characteristics (Gurel *et al.*, 2013). These data suggest that the known association between diabetes mellitus and ischemic cardiovascular disease may partly stem from alterations at the level of cardiac HKII expression. More work is needed to fully explore the role of HKII in diabetic cardiomyopathy.

Mechanisms of mtHKII-induced protection against IR injury (Figure 2):

There is currently no consensus concerning the exact mechanism of mtHK protection against IR injury. Below we restrict our discussion to those four mechanisms for which experimental evidence can be found. The overarching action of mtHK is its regulatory role in the homeostatic cross-talk between the mitochondria and the cell. This cross-talk is set by the degree of permeability of the OMM and the IMM to extramitochondrial metabolites. The permeability of the OMM is determined by VDAC, the mitochondrial binding partner of HK. HK, at least partly, regulates the permeability of VDAC for many important metabolites such as ATP, ADP, NADH (Rostovtseva *et al.*, 2005). The permeability barrier of the IMM to protons and ions is essential to ATP synthesis by mitochondria; loss of this permeability barrier prevents the generation of an electrochemical gradient (mitochondrial potential) that drives ATP synthesis through the F₀F₁ATPase. This loss of the IMM permeability barrier, as reflected by the opening of a non-specific pore in the IMM, the so-called mPTP, is currently considered the final event causing IR injury and irreversible cell death (Halestrap *et al.*, 2009). The molecular identity of the mPTP was recently suggested to consist of dimers of the F₀F₁ATPase localised on the IMM (Giorgio, 2013), with HK, VDAC, ANT and CypD as important regulators of the mPTP (see also Figure 2). It is through this mPTP complex that HK mediates its decisive role in IR injury and cardioprotection. It should be noted that there may also be a role for the mitochondrial phosphate carrier (PiC) as important regulator of the mPTP (Leung *et al.*, 2008). The reader is directed to literature that discusses this component in detail (Halestrap, 2009; Leung and Halestrap, 2008). For this review we focus primarily on how HK may affect the mPTP.

1) Prevention of conformational change in molecular mPTP regulation complex to stabilize mitochondrial membrane potential. It has been shown that mitochondrial depolarization occurs during cardiac ischemia and may be an early sign of irreversible injury (Lyon *et al.*, 2010). Mitochondrial depolarization during ischemia and early reperfusion may cause direct mPTP opening (Bernardi, 1992), and there is evidence that mtHKII may prevent such depolarization. We have recently demonstrated that acute HKII detachment from mitochondria in the beating heart per se (without any concomitant stress signal), using medium-to-high dosage ($\geq 2.5 \mu\text{M}$) of a HKII dislodging peptide, acutely depolarized mitochondria and induced cell death, an effect which could not be explained by vascular obstruction or ensuing ischemia in the intact organ (Smeele *et al.*, 2011A; Nederlof *et al.*, 2013). In these conditions of normoxic perfusion with a pH > 7 buffer, this depolarization can cause immediate mPTP opening and cell death (Bernardi, 1992). Previously, Chiara *et al.* (2008) demonstrated that the sensitivity of isolated cardiomyocytes to ROS-induced mPTP opening was much increased with low concentrations (< 1 μM) of the HKII dislodging peptide. They hypothesized that detachment of HKII induced a conformational change in the molecular complex connecting the OMM with the IMM and the mPTP (Chiara *et al.*, 2008). We would suggest that the HKII dislodging peptide fully opens VDAC, either due to loss of HK or other VDAC-regulating proteins, such as tubulin (Sheldon *et al.*, 2013). VDAC is the most abundant protein of the OMM and is responsible for the transport of ADP/ATP and other metabolites (e.g, NADH, Ca²⁺) across the OMM (Colombini, 2004; Rostovtseva *et al.*, 2005; 2008A). VDAC can change between an open and “closed” state, which is almost impermeable to ADP and ATP, and may thereby regulate mitochondrial respiration. The binding of several cytosolic proteins (tubulin, tBid, Bcl-x_L, HK) with VDAC, in combination with OMM lipid composition and trans-membrane potential, regulate VDAC conductance. It was recently demonstrated that dimeric tubulin, known to interact with mitochondria in vivo, induced voltage-sensitive closure of VDAC, reducing ADP availability and thereby

mitochondrial respiration (Rostovtseva *et al.*, 2008B). Preliminary data (Sheldon *et al.*, 2013) now shows that the HKII dislodging peptide disrupts HKII and tubulin binding to VDAC in planar lipid bilayers, resulting in unregulated permeability of VDAC that may ultimately result in large ADP influx, decreasing the mitochondrial membrane potential to a critical level of spontaneous mPTP opening.

2) Stabilization of mitochondrial contact sites during ischemia preventing CytC release.

mtHKII may alternatively prevent OMM rupture and/or permeabilisation by stabilization of mitochondrial contact sites. Hexokinase is preferentially bound to mitochondria at locations where the IMM comes closest to the OMM (Brdiczka *et al.*, 2006). These contact sites contain large protein complexes consisting of VDAC, ANT, cytochrome C, benzodiazepine receptor, cyclophilin D, cardiolipin, HK and creatine kinase. In reconstituted vesicles, disruption of HK from these protein complexes increases their permeability, which could be interpreted as analogous to increased permeability of the OMM and/or mPTP (Beutner *et al.*, 1998). It has been suggested that during ischemia, progressive acidosis and G6P accumulation dislodge HK from mitochondria (Pasdois *et al.*, 2013). Such decrease in mtHK, together with increased Ca^{2+} , disrupts the contact sites resulting in an increased permeability of the OMM for cytochrome c release. Knowing that oxidized cytochrome C is an important anti-oxidant, the loss of cytochrome C will result in increased ROS production at early reperfusion (Pasdois *et al.*, 2011, 2013), finally resulting in mPTP opening and infarction.

3) Maintaining mitochondrial ADP to inhibit mPTP and reduce ROS. The activity of HK at the mitochondrial surface rapidly returns ADP back to the inner mitochondrial compartment via VDAC and ANT, thereby ensuring high levels of ADP in the vicinity of F_0F_1 ATPase dimers at early reperfusion. This “ATP/ADP” shuttle has been shown to reduce the mitochondrial membrane potential and limit ROS production (Da-Silva *et al.*, 2004; Santiago *et al.*, 2008; Wu *et al.*, 2012). The reduction in ROS production offered by active mtHK can range from >90% (going from zero to normal mtHK levels in isolated brain mitochondria; Da-Silva *et al.*, 2004), to 70% (with activation of mtHK in isolated rat heart mitochondria; Santiago *et al.*, 2008) and to 20% (with 40% increase in mtHKII in neonate rat cardiomyocytes; Wu *et al.*, 2012).

4) Inhibition of ATP hydrolysis during ischemia. Maintaining HKII at the mitochondria during ischemia may impair cytosolic ATP entrance into the mitochondria (Perevoshchikova *et al.*, 2010) during ischemia, thereby attenuating mitochondrial hydrolysis of cytosolic ATP (through reversed mode of mitochondrial F_1F_0 ATPsynthase). Prevention of a critical depletion of ATP by the mitochondria during ischemia can significantly reduce anaerobic glycolysis and lactate accumulation, cardiac contracture and cell death induced by IR interventions (Steenbergen *et al.*, 1990; Jennings, 2013).

Structural obstruction of pro-apoptotic protein binding to mitochondria. It has been proposed, in cellular studies employing oxidant agents, that mtHKII may be cytoprotective through structural opposition to the mitochondrial binding of pro-apoptotic proteins such as Bax or Bad (Pastorino *et al.*, 2002). However, we and others have been unable to show a role for Bax in mtHKII-mediated protection against IR injury in isolated hearts (Smeele *et al.*, 2011A; Pasdois *et al.*, 2013) or skeletal muscle (Smeele *et al.*, 2012). The purely structural basis of mtHKII cytoprotection by steric hindrance is also challenged by several studies which demonstrate that glucose must be present in order for HK to offer protection against cell death (Gottlob *et al.*, 2001; Mergenthaler *et al.*, 2013). Furthermore, Majewski *et al.* (2004) demonstrate that the protection offered through hexokinase-mitochondria interaction does not necessitate the presence of Bax and Bak. Thus, it seems that Bax and Bad do not play a significant role in mtHKII protection against IR injury.

Targeting Hexokinase to Mitochondria (Figure 3)

It is clearly established in numerous cardiovascular disease models and in skeletal muscle ischemia-reperfusion interventions that the amount of HKII bound to mitochondria is a major determinant of infarct size and/or disease progression (Smeele *et al.*, 2010, 2011A, 2012; Wu *et al.*, 2011, 2012). In fact, the Halestrap laboratory recently reported a strong inverse correlation between the amount of end-ischemic mtHKII and infarct size in the isolated rat heart subjected to different perfusion condition: tripling of mtHKII reduced infarct size from 65% to 5% (see Fig. 9, Pasdois *et al.*, 2013). Development of new therapies directed at increasing and/or keeping HKII at the mitochondria therefore seems like an attractive cardioprotective approach. Below we summarize the most promising interventions which have been shown to raise total HK or specifically mtHKII, for exploration of their (clinical) potential as adjunct therapy in settings of ischemia-reperfusion and possible chronic diseases such as diabetes, cardiac hypertrophy and heart failure.

“Conditioning” of the heart: In 2005 we demonstrated that an IPC stimulus immediately translocates HK to the mitochondria in isolated rat hearts (Zuurbier *et al.*, 2005). Subsequently, we have also shown that IPC also prevents HKII detachment from mitochondria during the irreversible period of ischemia (Gürel *et al.*, 2009). These studies were later partly confirmed by Pasdois *et al.* (2011, 2013). Such IPC interventions can be performed clinically for leg or arm surgeries, but applicability for the heart is not directly feasible. However, the discovery that the heart can also be protected through remote ischemic preconditioning (RIPC) or post-conditioning, opened an avenue to cardiac application of the “conditioning” phenomenon. Since the intracellular signalling pathways providing protection with IPC overlap to a large extent with those of RIPC (e.g. Li *et al.*, 2011), it is anticipated that RIPC may also translocate HKII to mitochondria. This information is however lacking in the literature. Our currently active clinical mtHK-RIPC trial (NTR2915, Nederlands Trial Register) of RIPC in CABG patients, examines the relationship between RIPC protection and mtHKII in human atrial tissue, and will hopefully provide this much needed information.

Insulin/PI3/Akt/GSK-3 β –axis: Several studies have demonstrated that activation of this pathway will acutely (< 30 min) increase HKII trafficking to the mitochondria (Russell *et al.*, 1992; Pastorino *et al.*, 2005; Zuurbier *et al.*, 2005, Southworth *et al.*, 2007; Miyamoto *et al.*, 2008) and later on increases HKII expression. Juhaszova *et al.* (2004) demonstrated that many cardioprotective agents confer protection through phosphorylation of GSK-3 β and consequently inhibition of mPTP. Although many other studies can subsequently be found that have demonstrated cardioprotection with activation of this pathway, none of them have directly examined whether this was due to increased mtHKII (e.g. Ng *et al.*, 2012; Terashima *et al.*, 2010; Hausenloy *et al.*, 2005). A disadvantage of using this pathway to advance mtHKII is of course its pleiotropic character, with unwanted side effects increasing with every step upstream above HKII. For example, insulin may increase HKII translocation to mitochondria, but at the same time may not only result in hypoglycemia, but also in hypolipidemia (Zuurbier *et al.*, 2008). It therefore seems advisable to use more specific treatment for increasing mtHKII.

Anesthesia: The use of specific anaesthetics for providing protection against IR injury is an attractive scenario in surgeries that necessitate anaesthesia. Pre-clinical studies in healthy, young animals almost all report protective effects of certain volatile anaesthetics (sevoflurane, isoflurane) and opiates (morphine). These protective anaesthetics also commonly activate the PI3/Akt/GSK-3 β axis. However, these protective effects were not always observed in clinical studies employing e.g. CABG procedures (De Hert *et al.*, 2011). The ambiguity in the clinical

scenario potentially results from co-morbidities (diabetes, aging, and hypertrophy) and co-medications (e.g. statins, dexamethasones, opioids, nitroglycerine, β -blockers) which disturb the signalling pathway. Using several different anaesthetic regimens in healthy rats, we were able to demonstrate that the cardioprotective volatile anaesthetics sevoflurane and isoflurane did indeed maintain HK at cardiac mitochondria at a level similar to the non-anaesthetised animal (Zuurbier *et al.*, 2008). An anaesthetic regimen of propofol-sufentanil-morphine, also often used in the clinical arena, resulted in solubilisation of HK from the mitochondria. It can be speculated that the divergent effects of these two clinically most used anaesthetic regimens (volatile anaesthesia versus fentanyl-propofol anaesthesia) on mtHKII may also explain the dissipating effect of propofol anaesthesia on RPC protection (Kottenberg *et al.*, 2012). Further studies will be needed to test this hypothesis directly. In conclusion, although certain anaesthetics may indeed offer protection through increases in mtHKII, the many cellular signalling steps that exist between the start of protection induced by an anaesthetic agent to the final subcellular HKII translocation is prone to be disturbed by many clinical and disease factors, thereby decreasing its likeliness as an ideal option offering IR protection under clinical conditions.

Metformin: The glucose-lowering anti-diabetic drug metformin has been shown to be cardioprotective beyond its antihyperglycemic properties. It reduces infarct size in both diabetic and non-diabetic animals (Whittington *et al.*, 2013; Bhamra *et al.*, 2008; Calvert *et al.*, 2008; Solskov *et al.*, 2008). In addition, multiple clinical studies showed reduced cardiovascular mortality in diabetic patients treated with metformin (El Messaoudi *et al.*, 2013). These cardioprotective effects may be caused by increased mtHK activity. Metformin treatment reverses the downregulation in total HK activity, and has been shown to increase HK translocation to the mitochondria in diabetic hearts without adversely affecting normal hearts (Da Silva *et al.*, 2012). Whether metformin will increase (mt)HK in hearts during IR to afford protection remains to be examined, but 2 weeks of metformin treatment has previously been demonstrated to increase HK activity in rat white gastrocnemius muscle (Suwa *et al.*, 2006). This increase in HK might be explained by an increase in Akt phosphorylation after metformin treatment during reperfusion (Bhamra *et al.*, 2008). However, Akt phosphorylation was not observed when metformin was given before ischaemia (Bhamra *et al.*, 2008; Calvert *et al.*, 2008). Alternatively, metformin may increase HK activity through activation of AMPK. Increases in AMPK activity have been associated with increased HK activity in skeletal muscle (Holmes *et al.*, 1999; Dieni & Storey, 2011). Metformin may activate AMPK through increases in AMP resulting from inhibition of complex I (Owen *et al.*, 2000) and/or AMP deaminase (Ouyang *et al.*, 2011; Vytla *et al.*, 2013). Metformin is one of the most long-standing prescribed drugs in diabetes, showing relatively high efficacy. It will be interesting to elucidate whether a common mechanism of this drug entails the translocation of HK to the mitochondria, to identify a cellular mechanism for its cardioprotective effects.

miR-155/miR-143 therapy: MicroRNAs (miR) have recently been discovered as yet another level of regulation in biological function. miRs are non-protein-coding RNAs of 20-30 nucleotides, which silence gene expression at the post-transcriptional level by targeting the 3'-untranslated region of messenger RNA. The use of miR therapeutics in cardiovascular medicine is only starting to develop, although several studies have already demonstrated the feasibility of such an approach (Thum, 2011). HKII has been shown to be regulated by miR-155 and miR-143 in cancer cells (Jiang *et al.*, 2012; Peschiaroli *et al.*, 2012). Increases in miR-155 induced HKII expression through activation of a HKII transcriptional activator (STAT3) and repression of a negative regulator of HKII, miR-143. Matkovich *et al.* (2013) recently demonstrated that cardiac overexpression of miR-143 was also able to suppress HKII mRNA in the heart with no indirect target regulation. Therapies may therefore be developed which

employ synthetic complementary oligonucleotides against miR-143 and/or adeno-associated virus containing miR-155 to specifically increase cardiac HKII and offer protection during IR interventions.

Heat shock proteins: HKII has recently shown to be released from mitochondria in tumour cells during inhibition of mitochondrial HSP90 (Chae *et al.*, 2012). HSP90 has previously been demonstrated to have cardioprotective capacity (Latchman *et al.*, 2001; Xiang *et al.*, 2010) and the mitochondrial heat shock protein, tumour necrosis factor receptor-associated protein 1 (TRAP1), is known to be present in the heart (Xiang *et al.*, 2010). A therapy directed at increasing mitochondrial HSPs, either through heat treatment or gene therapy, may therefore also have cardioprotective potential by increasing mtHKII.

Detrimental effects of persistent elevated mtHKII in the heart?

The previous sections illustrate the many pro-survival effects of augmenting HKII-mitochondria binding within the heart. This raises the question that if mtHKII is such a powerful protector of the myocardium, why is HKII not permanently bound to mitochondria in the healthy heart? We hypothesize that irreversibly bound mtHK would hamper the natural occurrence of mitochondrial depolarisation needed to maintain mitochondria healthy. Since mitochondrial depolarisation is a trigger signal for mitochondrial recycling through mitophagy, prevention of depolarisation may result in accumulation of dysfunctional mitochondria and ultimately a dysfunctional heart. This is supported by the apparent benefit afforded by dichloroacetate (DCA) in the treatment of pulmonary hypertension, right heart failure (McMurtry *et al.*, 2004), hyperthyroid hypertrophy (Atherton *et al.*, 2011) and cancer (Bonnet *et al.*, 2007; Michelakis *et al.*, 2010). DCA induces mitochondrial depolarisation, which may at least partly be explained through disruption of hexokinase-mitochondrial binding (Michelakis *et al.*, 2010). The often observed hyperpolarised mitochondria in cancer cells (Bonnet *et al.*, 2007; Chen *et al.*, 1988) is consistent with their increased mtHKII as characterised by the Warburg effect. Permanently increasing mtHKII binding would also increase baseline aerobic glycolysis, and subsequently retard cellular signalling and mitochondrial activation, required for rapid responsive change in cardiac workload (Zuurbier *et al.*, 2002; Harrison *et al.*, 2003). Such retardation of mitochondrial activation may temporarily impair the free energy of ATP hydrolysis through elevation of cytosolic ADP (Van Beek *et al.*, 1998). Finally, the upregulated glycolysis caused by permanent association of HK to cardiac mitochondria would presumably switch off fatty acid oxidation through the Randle effect, resulting in a less efficient heart when oxygen is not limiting, and a redirection of fatty acids towards lipid accumulation in the heart. The chronic elevated glucose uptake may also result in an increased accumulation of glucose-6-phosphate, resulting in chronic mTOR activation concomitant with an activated ER stress response (Sen *et al.*, 2013). Interestingly, lipid accumulation, chronic mTOR activation and ER stress are all biochemical markers of cardiac failure (Sharma *et al.*, 2004; Shioi *et al.*, 2003), a known condition with elevated cardiac HK. It should be realised that the schemes discussed above are purely hypothetical, no evidence currently exists that has demonstrated detrimental effects of excessive mtHKII levels for the heart. However, future work may be devised to provide answers to these important questions of possible detrimental effects of too much mtHKII for the heart.

In conclusion, the association of HKII with mitochondria is a critical determinant of cardiomyocyte death, making it a potential drug target in the treatment of cardiovascular ischemic diseases. It seems that in HK-mitochondrial binding, the two human diseases with

the largest impact on human mortality and morbidity, cancer and cardiovascular disease, share a similar, but directionally opposing, cellular mechanism: mtHK binding is *increased* in malignant cancer providing it with resilience against cell death, whereas it is *decreased* during cardiac infarction and thereby contributes to cardiac cell death. The challenge is now to target this mechanism which governs whether cells live or die in the treatment of cardiovascular diseases, with a minimum of collateral damage.

Supported by a grant of the Dutch Heart Foundation (NHS2010B011)

Conflict of Interests: None

Accepted Article

References

- Abraham S, Borrebaeck B, Chaikoff IL (1964). Effect of dietary carbohydrates on glucokinase and mannokinase activities of various rat tissues. *J Nutr* **83**: 273-288.
- Ahmad A, Ahmad S, Schneider BK, Allen CB, Chang L-y, White CW (2002). Elevated expression of hexokinase II protects human lung epithelial-like A549 cells against oxidative injury. *Am J Physiol Lung Cell Mol Physiol* **283**: L573-L584.
- Atherton HJ, Dodd MS, Heather LC, Schroeder MA, Griffin JL, Radda JL, *et al.* (2011). Role of pyruvate dehydrogenase inhibition in the development of hypertrophy in the hyperthyroid rat heart: a combined magnetic resonance imaging and hyperpolarized magnetic resonance spectroscopy study. *Circulation* **123**: 2552-2561.
- Bhamra GS, Hausenloy DJ, Davidson SM, Carr RD, Paiva M, Wynne AM, *et al.* (2008). Metformin protects the ischemic heart by the Akt-mediated inhibition of mitochondrial permeability transition pore opening. *Basic Res Cardiol* **103**: 274-284.
- Beutner G, Ruck A, Riede B, Brdiczka D (1998). Complexes between porin, hexokinase, mitochondrial creatine kinase and adenylate translocator display properties of the permeability transition pore. Implications for regulation of permeability transition by the kinases. *Biochim Biophys Acta-Biomembr* **1368**: 7-18.
- Bernardi P (1992). Modulation of the mitochondrial cyclosporin A-sensitive permeability transition pore by the proton electrochemical gradient. *J Biol Chem* **267**: 8834-8839..
- Bessmann SP, Geiger PJ (1980). Compartmentation of hexokinase and creatine kinase phosphokinase, cellular regulation, and insulin action. In: Horecker BL, Stadtman ER (eds). *Current topics in cellular regulation*, Academic, New York, **16**: 55-86.
- Birsoy K, Wang T, Possemato R, Yilmaz OH, Koch CE, Chen WW *et al.* (2013). MCT1-mediated transport of a toxic molecule is an effective strategy for targeting glycolytic tumors. *Nat Gen* **45**: 104-108.
- Bonnet S, Archer SL, Allalunis-Turner J, Haromy A, Beaulieu C, Thompson R, *et al.* (2007). A mitochondria-K⁺ channel axis is suppressed in cancer and its normalization promotes apoptosis and inhibits cancer growth. *Cancer Cell* **11**: 37-51.
- Brdiczka D (1990). Interaction of mitochondrial porin with cytosolic proteins. *Experientia* **46**, 161-167.
- Brdiczka DG, Zorov DB, Sheu SS (2006). Mitochondrial contact sites: their role in energy metabolism and apoptosis. *Biochim Biophys Acta* **1762**: 148-163.
- Bryson JM, Coy PE, Gottlob K, Hay N, Robey RB (2002). Increased hexokinase expression of either ectopic or endogenous origin, protects renal epithelial cells against acute oxidant-induced cell death. *J Biol Chem* **277**: 11392-11400.

Bustamante E, Pedersen PL (1977). High aerobic glycolysis of rat hepatoma cells in culture: role of mitochondrial hexokinase. *Proc Natl Acad Sci* **74**: 3735-3739.

Bustamante E, Morris HP, Pedersen PL (1981). Energy metabolism of tumor cells. Requirements for a form of hexokinase with a propensity for mitochondrial binding. *J Biol Chem* **256**: 8699-8704.

Calvert JW, Gundewar S, Jha S, Greer JJ, Bestermann WH, Tian R *et al.* (2008). Acute metformin therapy confers cardioprotection against myocardial infarction via AMPK-eNOS-mediated signaling. *Diabetes* **57**: 696-705.

Chae YC, Caino MC, Lisanti S, Ghosh JC, Dohi T, Danial NN, *et al.* (2012). Control of tumor bioenergetics and survival stress signalling by mitochondrial HSP90s. *Cancer Cell* **22**: 331-344.

Chiara F, Castellaro D, Marin O, Petronilli V, Brusilow WS, Juhaszova M, *et al.* (2008). Hexokinase II detachment from mitochondria triggers apoptosis through the permeability transition pore independent of voltage-dependent anion channels. *PLoS One* **3**:e1852.

Chen LB (2013). Mitochondrial membrane potential in living cells. *Annu Rev Cell Biol* **4**: 155-181.

Colombini M (2004). VDAC: The channel at the interface between mitochondria and the cytosol. *Mol Cell Biochem* **256-257**: 107-115.

Corona JC, Gimenez-Cassina A, Lim F, Diaz-Nido J (2010). Hexokinase II gene transfer protects against neurodegeneration in the rotenone and MPTP mouse models of Parkinson's disease. *J Neurosci Res* **88**: 1943-1950.

Correa F, Garcia N, Gallardo-Perez JC, Carreno-Fuentes L, Rodrigues-Enriques S, Marin-Hernandez A, Zazueta C (2008). Post-conditioning preserves glycolytic ATP during early reperfusion: A survival mechanism for the reperfused heart. *Cell Physiol Biochem* **22**: 635-644.

Crane RK, Sols A (1953). The association of hexokinase with particulate fractions of brain and other tissue hoogenates. *J Biol Chem* **203**: 273-292.

Da Silva D, Ausina P, Alencar EM, Coelho WS, Zancan P, Sola-Penna M (2012). Metformin reverses hexokinase and phosphofructokinase downregulation and intracellular distribution in the heart of diabetic mice. *IUBMB Life*: **64**, 766-774.

Da-Silva WS, Gomez-Puyou A, de Gomez-Puyou MT, Moreno-Sanchez R, de Felice FG, de Meis L, *et al.* (2004). Mitochondrial bound hexokinase activity as a preventive antioxidant defense : steady-state ADP formation as a regulatory mechanism of membrane potential and reactive species generation in mitochondria. *J Biol Chem* **279**: 39846-39855.

De Hert SG (2011). Cardioprotection by volatile anesthetics: What about noncardiac surgery? *J Cardiothorac Vasc Anesth* **25**:899-901.

De Jong JW, Hülsmann WC (1970). Effects of nagarse, adenosine and hexokinase on palmitate activation and oxidation. *Biochim Biophys Acta* **210**: 499-501.

Dieni CA, Storey KB (2011). Regulation of hexokinase by reversible phosphorylation in skeletal muscle of a freeze-tolerant frog. *Comp Biochem Physiol B Biochem Mol Biol* **159**: 236-243.

El Messaoudi S, Rongen GA, Riksen NP (2013). Metformin therapy in diabetes: the role of cardioprotection. *Curr Atheroscler Rep* **15**, 314.

Fiek C, Benz R, Roos N, Brdiczka D (1982). Evidence for identity between the hexokinase-binding protein and the mitochondrial porin in the outer membrane of rat liver mitochondria. *Biochim Biophys Acta* **688**, 429-440.

Forte M, Adelsberger-Mangan D, Colombini M (1987). Purification and characterization of the voltage-dependent anion channel from the outer mitochondrial membrane of yeast. *J Membrane Biol* **99**, 65-72.

Furuta H, Nishi S, Le Beau MML, Fernald AA, Yano H, Bell GI (1996). Sequence of human hexokinase III cDNA and assignment of the human hexokinase III gene (*HK3*) to chromosome band 5q35.2 by fluorescence *in situ* hybridization. *Genomics* **36**: 206-209.

Gall JM, Wong V, Pimental DR, Havasi A, Wang Z, Pastorino JG, *et al.* (2011). Hexokinase regulates Bax-mediated mitochondrial membrane injury following ischemic stress. *Kidney Int* **79**: 1207-1216.

Gimenez-Cassina A, Lim F, Palomo GM, Diaz-Nido J (2009). Mitochondrial hexokinase II promotes neuronal survival and acts downstream of glycogen synthase kinase-3. *J Biol Chem* **284**: 3001-3011.

Giorgio V, von Stockum S, Antoniel M, Fabbro A, Fogolari F, Forte M, *et al.* (2013). Dimers of mitochondrial ATP synthase form the permeability transition pore. *Proc Natl Acad Sci USA* **110**: 5887-5892.

Goldin N, Arzoine L, Heyfets A, Israelson A, Zaslavsky Z, Bravman T *et al.* (2008). Methyl jasmonate binds to and detaches mitochondria-bound hexokinase. *Oncogene* **27**: 4636-4643.

Gottlob K, Majewski N, Kennedy S, Kandel E, Robey RB, Hay N (2001). Inhibition of early apoptosis events by Akt/PKB is dependent on the first committed step of glycolysis and mitochondrial hexokinase. *Genes Dev* **15**: 1406-1418.

Gürel E, Smeele KM, Eerbeek O, Koeman A, Demirci C, Hollmann MW *et al.* (2009). Ischemic preconditioning affects hexokinase activity and HKII in different subcellular compartments throughout cardiac ischemia-reperfusion. *J Appl Physiol* **106**: 1909-1916.

Gürel E, Ustunova S, Kapucu A, Yilmazer N, Eerbeek O, Nederlof R *et al.* (2013). Hexokinase cellular trafficking in ischemia-reperfusion and ischemic preconditioning is altered in type I diabetic heart. *Mol Biol Rep* **40**: 4153-4160.

Groen AK, Wanders RJA, Westerhoff HV, van der Meer R, Tager JM (1982). Quantification of the contribution of various steps to the control of mitochondrial respiration. *J Biol Chem* **257**: 2754-2757.

Halestrap A (2009). What is the mitochondrial permeability transition pore? *J Mol Cell Cardiol* **46**:821-831.

Harrison GJ, Van Wijhe MH, de Groot B, Dijk FJ, Gustafson LA, van Beek JH (2003). Glycolytic buffering affects cardiac bioenergetic signaling and contractile reserve similar to creatine kinase. *Am J Physiol Heart Circ Physiol* **285**: H883-H890.

Hausenloy D, Tseng A, Mocanu MM, Yellon DM (2005). Ischemic preconditioning protects by activating prosurvival kinases at reperfusion. *Am J Physiol Heart Circ Physiol* **288**: H971-H976.

Heikkinen S, Suppola S, Malkki M, Deeb SS, Jänne J, Laakso M (2000). Mouse hexokinase II gene: structure, cDNA, promotor analysis, and expression pattern. *Mamm Genome* **11**: 91-96.

Heumann S, Falkenberg F, Pfeleiderer G (1974). Purification and immunological characterization of the human hexokinase isozymes I and III (ATP-D-hexose 6-phosphotransferase EC 2.7.1.1). *Biochim Biophys Acta* **334**:328-342.

Holmes BF, Kurth-Kraczek EJ, Winder WW (1999). Chronic activation of 5'-AMP-activated protein kinase increases GLUT-4, hexokinase, and glycogen in muscle. *J Appl Physiol* **87**:1990-1995.

Jennings RB (2013). Historical perspective on the pathology of myocardial ischemia/reperfusion injury. *Circ Res* **113**: 428-438.

Jiang S, Zhang LF, Zhang HW, Hu S, Lu MH, Liang S *et al.* (2012). A novel miR-155/miR-143 cascade controls glycolysis by regulating hexokinase 2 in breast cancer cells. *EMBO J* **31**: 1985-1998.

John S, Weiss JN, Ribalet B (2011). Subcellular localization of hexokinase I and II directs the metabolic fate of glucose. *PLoSOne* **6**:e17674.

Johnson MK (1960). The intracellular distribution of glycolytic and other enzymes in rat brain homogenates and mitochondrial preparations. *Biochem J* **77**: 610-618.

Juhaszova M, Zorov DB, Kim SH, Pepe S, Fu Q, Fishbein KW *et al.* (2004). Glycogen synthase kinase-3beta mediates convergence of protection signaling to inhibit the mitochondrial permeability transition pore. *J Clin Invest* **113**, 1535-1549.

Katzen HM, Soderman DD, Wiley CE (1970). Multiple forms of hexokinase. Activities associated with subcellular particulate and soluble fractions of normal and streptozotocin diabetic rat tissues. *J Biol Chem* **245**: 4081-4096.

Keith B, Johnson RS, Simon MC (2012). HIF1 α and HIF2 α : sibling rivalry in hypoxic tumour growth and progression. *Nat Rev Cancer* **12**: 9-22.

Ko YH, Verhoeven HA, Lee MJ, Corbin DJ, Vogl TJ, Pedersen PL (2012). A translational study “case report” on the small molecule “energy blocker” 3-bromopyruvate (3BP) as a potent anticancer agent: from bench side to bedside. *J Bioeng Biomembr* **44**: 163-170.

Kottenberg E, Thielmann M, Bergmann L, Heine T, Jakob H, Heusch G, Peters J (2012). Protection by remote ischemic preconditioning during coronary artery bypass graft surgery with isoflurane but not propofol - a clinical trial. *Acta Anaesthesiol Scand* **56**: 30-38.

Latchman DS (2001). Heat shock proteins and cardiac protection. *Cardiovasc Res* **51**: 637-646.

Leung AW, Varanyuwatana P, Halestrap AP (2008). The mitochondrial phosphate carrier interacts with cyclophilin D and may play a key role in the permeability transition. *J Biol Chem* **283**: 26312-26323.

Leung AW, Halestrap A (2008). Recent progress in elucidating the molecular mechanism of the mitochondrial permeability transition pore. *Biochim Biophys Acta* **1777**:946-952.

Li J, Xuan W, Yan, tropak MB, Jean-St-Michel E, Liang W, Gladstone R *et al.* (2011). Remote preconditioning provides potent cardioprotection via PI3K/Akt activation and is associated with nuclear accumulation of β -catenin. *Clin Sci* **120**: 451-462.

Lionetti V, Aquaro GD, Simioniuc A, di Cristofano C, Forini F, Cecchetti F, *et al.* (2009). Severe mechanical dyssynchrony causes regional hibernation-like changes in pigs with nonischemic heart failure. *J Cardiac Fail* **15**: 920-928.

Lyon AR, Joudrey PJ, Jin D, Nass RD, Aon MA, O'Rourke B, *et al.* (2010). Optical imaging of mitochondrial function uncovers actively propagating waves of mitochondrial membrane potential collapse across intact heart. *J Mol Cell Cardiol* **49**: 565-575.

Majewski N, Nogueira V, Bhaskar P, Coy PE, Skeen JE, Gottlob K, *et al.* (2004). Hexokinase-mitochondria interaction mediated by Akt is required to inhibit apoptosis in the presence or absence of Bax and Bak. *Mol Cell* **16**: 819-830.

Mandarino LJ, Printz RL, Cusi KA, Kinchington P, O'Doherty R, Osawa H, *et al.* (1995). Regulation of hexokinase II and glycogen synthase mRNA, protein, and activity in human muscle. *Am J Physiol* **269**: E701-E708.

Matkovich SJ, Hu Y, Dorn II GW (2013). Regulation of cardiac microRNAs by cardiac microRNAs. *Circ Res* **113**:62-71.

Marzo I, Brenner C, Zamzami N, Susin SA, Beutner G, Brdiczka D, Remy R, Xie ZH, Reed JC, Kroemer G (1998). The permeability transition pore complex: A target for apoptosis regulation by caspases and Bcl-2-related proteins. *J Exp Med* **187**, 1261-1271.

Mathupala SP, Ko YH, Pedersen PL (2009). Hexokinase-2 bound to mitochondria: Cancer's stygian link to the “Warburg effect” and a pivotal target for effective therapy. *Semin Cancer Biol* **19**: 17-24.

McFalls EO, Murad B, Liow JS, Gannon MC, Haspel HC, Lange A *et al.* (2002). Glucose uptake and glycogen levels are increased in pig heart after repetitive ischemia. *Am J Physiol Heart Circ Physiol* **282**: H205-H211.

McMurtry MS, Bonnet S, Wu X, Dyck JR, Haromy A, Hashimoto K, *et al.* (2004). Dichloroacetate prevents and reverses pulmonary hypertension by inducing pulmonary artery smooth muscle cell apoptosis. *Circ Res* **95**: 830-840.

Mergenthaler P, Kahl A, Kamitz A, van Laak V, Stohlmann K, Thomsen S, *et al.* (2012). Mitochondrial hexokinase II (HKII) and phosphoprotein enriched in astrocytes (PEA15) form a molecular switch governing cellular fate depending on the metabolic state. *Proc Natl Acad Sci USA* **109**: 1518-1523.

Michelakis ED, Sutendra G, Dromparis P, Webster L, Harmony A, Niven E, *et al.* (2010). Metabolic modulation of glioblastoma with dichloroacetate. *Sci Transl Med* **2**: 31ra34.

Miki T, Itoh T, Sunaga D, Miura T (2012). Effects of diabetes on myocardial infarct size and cardioprotection by preconditioning and postconditioning. *Cardiovasc Diabetol* **11**:67

Miyamoto S, Murphy AN, Brown JH (2008). Akt mediates mitochondrial protection in cardiomyocytes through phosphorylation of mitochondrial hexokinase-II. *Cell Death Differ* **15**: 521-9.

Miyamoto S, Purcell NH, Smith JM, Gao T, Whittaker R, Huang K, *et al.* (2010). PHLPP-1 negatively regulates Akt activity and survival in the heart. *Circ Res* **107**:476-484.

Murry CE, Jennings RB, Reimer KA (1986). *Circulation* **74**: 1124-1136.

Murphy E, Steenbergen C (2008). Mechanisms underlying acute protection from cardiac ischemia-reperfusion injury. *Physiol Rev* **88**: 581-590.

Nakashima RA, Mangan PS, Colombini M, Pedersen PL (1986). Hexokinase receptor complex in hepatoma mitochondria: evidence from N,N'-dicyclohexylcarbodiimide-labeling studies for the involvement of the pore-forming protein VDAC. *Biochemistry* **25**, 1015-1021.

Ng KW, Allen ML, Desai A, Macrae D, Pathan N (2012). Cardioprotective effects of insulin: How intensive insulin therapy may benefit cardiac surgery patients. *Circulation* **125**: 721-728.

Nederlof R, Xie C, Eerbeek O, Koeman A, Milstein DMJ, Hollmann MW *et al.* (2013). Pathophysiological consequences of TAT-HKII peptide administration are independent of impaired vascular function and ensuing ischemia. *Circ Res* **112**: e8-e13.

Ouyang J, Parakhia RA, Ochs RS (2011). Metformin activates AMP kinase through inhibition of AMP deaminase. *J Biol Chem* **286**: 1-11.

Owen MR, Doran E, Halestrap AP (2000). Evidence that metformin exerts its anti-diabetic effects through inhibition of complex 1 of the mitochondrial respiratory chain. *Biochem J* **348**: 607-614.

Pasdois P, Parker JC, Griffiths EJ, Halestrap AP (2011). The role of oxidized cytochrome c in regulating mitochondrial reactive oxygen species production and its perturbation in ischaemia. *Biochem J* **436**: 493-505.

Pasdois P, Parker JE, Halestrap AP (2013). Extent of mitochondrial hexokinase II dissociation during ischemia correlates with mitochondrial cytochrome c release, reactive oxygen species production, and infarct size on reperfusion. *J Am Heart Assoc* **2**: e005645.

Pastorino JG, Hoek JB, Shulga N (2005) Activation of Glycogen Synthase Kinase 3{beta} Disrupts the Binding of Hexokinase II to Mitochondria by Phosphorylating Voltage-Dependent Anion Channel and Potentiates Chemotherapy-Induced Cytotoxicity. *Cancer Res* **65**: 10545–10554.

Pastorino JG, Shulga N, Hoek JB (2002). Mitochondrial binding of hexokinase II inhibits bax-induced cytochrome c release and apoptosis. *J Biol Chem* **277**: 7610-7618.

Pedersen PL (2007). Warburg, me and hexokinase 2: multiple discoveries of key molecular events underlying one of cancers' most common phenotypes, the "Warburg effect", i.e. elevated glycolysis in the presence of oxygen. *J Bioeng Biomembr* **39**: 211-222.

Penso J, Beitner R (1998). Clotrimazole and bifonazole detach hexokinase from mitochondria of melanoma cells. *Eur J Pharmacol* **342**: 113-117.

Perevoschchikova IV, Zorov SD, Kotova EA, Zorov DB, Antonenko YN (2010). Hexokinase inhibits flux of fluorescently labeled ATP through mitochondrial outer membrane porin. *FEBS Lett* **584**: 2397-2402.

Peschiaroli A, Giacobbe A, Formosa A, Markert EK, Bongiorno-Borbone L, Levine AJ, *et al.* (2012). miR-143 regulates hexokinase 2 expression in cancer cells. *Oncogene* **32**: 797-802.

Postic C, Shiota M, Magnuson MA (2001). Cell-specific roles of glucokinase in glucose metabolism. *Recent Prog Horm Res* **56**: 195-217.

Rabuazzo AM, Patane G, Anello M, Piro S, Vigneri R, Purrello F (1997). Hexokinase shift to mitochondria is associated with an increased sensitivity to glucose in rat pancreatic islets. *Diabetes* **46**: 1148-1152.

Riehle C, Wende AR, Zaha VG, Pires KM, Wayment B, Olsen C, *et al.* (2011). PCG-1 β deficiency accelerates the transition to heart failure in pressure overload hypertrophy. *Circ Res* **109**: 783-793.

Roosimaa M, Põdramägi, Kadaja L, Ruusalepp A, Paju K, Puhke R, *et al.* (2013). Dilation of human atria: increase diffusion restrictions for ADP, overexpression of hexokinase 2 and its coupling to oxidative phosphorylation in cardiomyocytes. *Mitochondrion* (Epub ahead of print) DOI: 10.1016/j.mito.2012.12.005.

Rostovtseva TK, Tan W, Colombini M (2005). On the role of VDAC in apoptosis: fact and fiction. *J Bioeng Biomem* **37**: 129-142.

Rostovtseva TK, Bezrukov SM (2008A). VDAC regulation: role of cytosolic proteins and mitochondrial lipids. *J Bioeng Biomem* **40**: 163-170.

Rostovtseva TK, Sheldon KL, Hassanzadeh E, Monge C, Saks V, Bezrukov SM, Sackett DL (2008B). Tubulin binding blocks mitochondrial voltage-dependent anion channel and regulates respiration. *Proc Natl Acad Sci USA* **105**: 18746-18751.

Russell RR 3rd, Mrus JM, Mommessin JI, Taegtmeier H (1992). Compartmentation of hexokinase in rat heart. A critical factor for tracer kinetic analysis of myocardial glucose metabolism. *J Clin Invest* **90**: 1972-1977.

Santagio AP, Chaves EA, Oliveira MF, Galina A (2008). Reactive oxygen species generation is modulated by mitochondrial kinases: correlation with mitochondrial antioxidant peroxidases in rat tissues. *Biochimie* **90**: 1566-1577.

Semenza GL (2003). Targeting HIF-1 for cancer therapy. *Nat Rev Cancer* **3**: 721-732.

Sen S, Kundu BK, Wu HC, Hashmi SS, Guthrie P, Locke LW, *et al.* (2013). Glucose regulation of load-induced mTOR signalling and ER stress in mammalian heart. *J Am Heart Assoc* **2**: e004796. doi: 10.1161/JAHA.113.004796

Sharma S, Adroque JV, Golfman L, Uray I, Lemm J, Youker K, *et al.* (2004). Intramyocardial lipid accumulation in the failing human heart resembles the lipotoxic rat heart. *Faseb J* **18**: 1692-1700.

Shaw RJ, Cantley LC (2006). Ras, PI(3)K and mTOR signalling controls tumour cell growth *Nature* **441**: 424-430.

Sheldon KL, Zuurbier CJ, Bezrukov SM, Rostovtseva TK (2013). Novel mechanism of mitochondrial respiration control through competition between hexokinase-2 and tubulin for VDAC binding. *Biophys J* **104** (Suppl. 1): p655a.

Shioi T, McMullen JR, tarnaevski O, Concorso K, Sherwood MC, Manning WJ, *et al.* (2003). Rapamycin attenuates load-induced cardiac hypertrophy in mice. *Circulation* **107**:1664-1670.

Smeele KMA, Southworth R, Wu R, Xie C, Nederlof R, Warley A, *et al.* (2011A). Disruption of hexokinase II-mitochondrial binding blocks ischemic preconditioning and causes rapid cardiac necrosis. *Circ Res* **108**: 1165-1169.

Smeele KM, Eerbeek O, Koeman A, Bezemer R, Ince C, Heikkinen S *et al.* (2010). Partial hexokinase II knockout results in acute ischemia-reperfusion damage in skeletal muscle of male, but not female, mice. *Pflug Arch* **459**: 705-712.

Smeele KM, Eerbeek O, Schaart G, Koeman A, Bezemer R, Nelson JK *et al.* (2012). Reduced hexokinase II impairs muscle function 2 wk after ischemia-reperfusion through increased cell necrosis and fibrosis. *J Appl Physiol* **113**: 608-618.

Smeele KM, ter Horst LH, Koeman A, Heikkinen S, Laakso M, Weber NC *et al.* (2011B). The effect of standard chow and reduced hexokinase II on growth, cardiac and skeletal muscle hexokinase and low-flow cardiac ischaemia-reperfusion injury. *Lab Anim* **45**: 160-166.

Solskov L, Lofgren B, Kristiansen SB, Jessen N, Pold R, Nielsen TT *et al.* (2008). Metformin induces cardioprotection against ischaemia/reperfusion injury in the rat heart 24 hours after administration. *Basic Clin Pharmacol Toxicol* **103**: 82-87.

Southworth R, Davey KA, Warley A, Garlick PB (2007). A reevaluation of the roles of hexokinase I and II in the heart. *Am J Physiol Heart Circ Physiol* **292**: H378–86.

Steenbergen C, Murphy E, Watts JA, London RE. (1990). Correlation between cytosolic free calcium, contracture, ATP, and irreversible ischemic injury in perfused rat heart. *Circ Res* **66** : 135-146.

Suwa M, Egashira T, Nakano H, Sasaki H, Kumagai S (2006). Metformin increases the PGC-1 α protein and oxidative enzyme activities possibly via AMPK phosphorylation in skeletal muscle in vivo. *J Appl Physiol* **101**: 1685-1692.

Terashima Y, Sato T, Yano T, Maas O, Itoh T, Miki T, *et al.* (2010). Role of phospho-GSK-3 β in myocardial protection afforded by activation of the mitochondrial K ATP channel. in *J Mol Cell Cardiol* **49**: 762-70.

Thum T (2011). MicroRNA therapeutics in cardiovascular medicine. *EMBO Mol Med* **4**, 3-14.

Xiang F, Huang YS, Shi XH, Zhang Q (2010). Mitochondrial chaperone tumour necrosis factor receptor-associated protein 1 protects cardiomyocytes from hypoxic injury by regulating mitochondrial permeability transition pore opening. *FEBS J* **277**: 1929-1938.

Yeih DF, Yeh HI, Lin LY, Tsay YG, Chiang FT, Tseng CD, *et al.* (2011). Enhanced activity and subcellular redistribution of myocardial hexokinase after acute myocardial infarction. *Int J Cardiol* **149**: 74-79.

Van Beek JHGM, Tian X, Zuurbier CJ, de Groot B, Van Echteld CJA, Eijgelshoven MHJ, *et al.* (1998). The dynamic regulation of myocardial oxidative phosphorylation: analysis of the response time of oxygen consumption. *Mol Cell Biochem* **184**: 321-344.

Vestergaard H, Bjørbaek C, Hansen T, Larsen FS, Granner DK, Pedersen O. (1995). Impaired activity and gene expression of hexokinase II in muscle from non-insulin-dependent diabetes mellitus patients. *J Clin Invest* **96**: 2639-2645.

Vytla VS, Ochs RS (2013). Metformin increases mitochondrial energy formation in L6 muscle cell cultures. *J Biol Chem* **288**: 20369-20377.

Warburg O, Posener K, Negelein E (1924). Ueber den Stoffwechsel der Tumoren. *Biochem Zeitschrift* **152**: 319-344.

Ward PS, Thompson CB (2012). Metabolic reprogramming: A cancer hallmark even Warburg did not anticipate. *Cancer Cell* **21**: 297-308.

Wei L, Zhou Y, dai Q, Qiao C, Zhao L, Lu N, Guo QL (2013). Oroxylin A induces dissociation of hexokinase II from the mitochondria and inhibits glycolysis by SIRT3-mediated deacetylation of cyclophilin D in breast carcinoma. *Cell Death Dis*
Doi:10.1038/cddis.2013.131

Whittington HJ, Hall AR, McLaughlin CP, Hausenloy DJ, Yellon DM, Mocanu MM (2013). Chronic metformin associated cardioprotection against infarction: not just a glucose lowering phenomenon. *Cardiovasc Drugs Ther* **27**: 5-16

Wilson JE (1995). Hexokinases. *Rec Physiol Biochem Pharmacol* **126**: 65-198.

Wilson JE (2003). Isozymes of mammalian hexokinase: structure, subcellular localization and metabolic function. *J Exp Biol* **206**: 2049-2057.

Wu R, Smeele KM, Wyatt E, Ichikawa Y, Eerbeek O, Sun L *et al.* (2011). Reduction in hexokinase II levels results in decreased cardiac function and altered remodelling after ischemia-reperfusion injury. *Circ Res* **108**: 60-69.

Wu R, Wyatt E, Chawla K, Tran M, Ghanefar M, Laakso M, *et al.* (2012). Hexokinase II knockdown results in exaggerated cardiac hypertrophy via increased ROS production. *EMBO Mol Med* **4**: 633-646.

Zuurbier CJ, Eerbeek O, Goedhart PT, Struys EA, Verhoeven NM, Jakobs C, *et al.* (2004). Inhibition of the pentose phosphate pathway decreases ischemia-reperfusion-induced creatine kinase release in the heart. *Cardiovasc Res* **62**: 145-153.

Zuurbier CJ, Eerbeek O, Meijer AJ (2005). Ischemic preconditioning, insulin, and morphine all cause hexokinase redistribution. *Am J Physiol Heart Circ Physiol.* **289**: H496-499.

Zuurbier CJ, Hoek FJ, van Dijk J, Abeling NG, Meijers JC, Levels JH, *et al.*, (2008). Perioperative hyperinsulinaemic normoglycaemic clamp causes hypolipidaemia after coronary artery surgery. *Brit J Anaesth* **100**: 442-450.

Zuurbier CJ, Ince C (2002). Post-ischaemic changes in the response time of oxygen consumption to demand in the isolated rat heart are mediated partly by calcium and glycolysis. *Pflügers Arch* **443**: 908-916.

Zuurbier CJ, Keijzers PJM, Koeman A, van Wezel HB, Hollmann MW (2008). Anesthesia's effects on plasma glucose and insulin and cardiac hexokinase at similar hemodynamics and without major surgical stress in fed rats. *Anesth Analg* **106**: 135-142.

Zuurbier CJ, Smeele KMA, Eerbeek O (2009). Mitochondrial hexokinase and cardioprotection of the intact heart. *J Bioenerg Biomembr* **41**: 181-185.

Zuurbier CJ, van Beek JHGM (1997). Mitochondrial response to heart rate steps in isolated rabbit heart is slowed after myocardial stunning. *Circ Res* **81**: 69-75.

Figure Legends

Figure 1 Schematic representation of cardiac disease states with low or high sensitivity to IR injury which is associated with protected mitochondria (high mtHK) or vulnerable mitochondria (low mtHK), respectively.

Figure 2 Schematic drawing of the mitochondrial permeability transition pore complex dictating cell death through decreases in mtHK induced by ischemia-reperfusion. The most likely mechanisms (1-4) through which disruption of hexokinase II – mitochondrial binding may cause cell death are displayed. (see text for further discussion).

Figure 3 Intracellular signalling pathways showing how different interventions (“conditioning”) and compounds such as cytokines, insulin, metformin, miRNA’s and anesthetics may increase HKII expression and/or HKII translocation to mitochondria. GPCR, G protein-coupled receptor; IR, insulin receptor ;JAK, Janus kinase; SOCS1, suppressor of cytokine signalling 1; STAT3, signal transducer and activator of transcription3; AMPK, AMP-activated protein kinase; PI3K, phosphoinositide 3-kinase; Akt, protein kinase B; PKC, protein kinase C; GSK, glycogen synthase kinase;C1, complex I of the electron transport chain.

Figure 1





Figure1.revised.jpg

Figure 2

c
y
t
o
p
l
a
s
m

m
i
t
o
c
h
o
n
d
r
i
o
n



possible mechanisms of cell death:

- 1) Unregulated permeability VDAC \rightarrow dissipation $\Delta\Psi_m \rightarrow \uparrow$ mPTP
- 2) \uparrow OMM permeabilization \rightarrow CytC release $\rightarrow \uparrow$ ROS $\rightarrow \uparrow$ mPTP
- 3) \downarrow ATP/ADP shuttle $\rightarrow \uparrow \Delta\Psi_m \rightarrow \uparrow$ ROS $\rightarrow \uparrow$ mPTP
- 4) \uparrow ATP into mitochondria $\rightarrow \uparrow$ ATP hydrolysis during ischemia \rightarrow critical ATP depletion $\rightarrow \uparrow$ mPTP

Figure2.revised.jpg

Figure 3




Figure3.revised.jpg